PYXS
Pyxis Oncology Inc
NASDAQ: PYXS · HEALTHCARE · BIOTECHNOLOGY
$1.70
+2.41% today
Updated 2026-04-30
Market cap
$106.81M
P/E ratio
—
P/S ratio
7.71x
EPS (TTM)
$-1.28
Dividend yield
—
52W range
$1 – $6
Volume
0.4M
Pyxis Oncology Inc (PYXS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $16.15M | $13.86M |
| Revenue growth (YoY) | — | — | — | — | — | — | -14.2% |
| Cost of revenue | — | $444000.00 | $1.25M | $1.84M | $2.00M | $475000.00 | $2.39M |
| Gross profit | — | $-444000.00 | $-1.25M | $-1.84M | $-2.00M | $15.67M | $11.47M |
| Gross margin | — | — | — | — | — | 97.1% | 82.8% |
| R&D | $1.22M | $8.60M | $51.05M | $86.13M | $49.59M | $58.75M | $73.70M |
| SG&A | $1.66M | $3.85M | $18.66M | $37.35M | $32.61M | $25.42M | $22.19M |
| Operating income | $-2.88M | $-12.89M | $-69.72M | $-123.48M | $-82.20M | $-89.46M | $-84.42M |
| Operating margin | — | — | — | — | — | -554.1% | -609.2% |
| EBITDA | $-2.77M | $-12.38M | $-69.07M | $-122.77M | $-80.27M | $-65.51M | $-79.91M |
| EBITDA margin | — | — | — | — | — | -405.8% | -576.6% |
| EBIT | $-2.88M | $-12.83M | $-69.72M | $-123.48M | $-82.20M | $-68.50M | $-84.42M |
| Interest expense | $0.00 | $0.00 | $6.26M | $2.76M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.67M | $-12.83M | $-75.97M | $-117.95M | $-73.79M | $-77.33M | $-79.62M |
| Net income growth (YoY) | — | -381.4% | -492.3% | -55.3% | +37.4% | -4.8% | -3.0% |
| Profit margin | — | — | — | — | — | -478.9% | -574.5% |